

UC Riverside

UC Riverside Previously Published Works

Title

Epithelial-to-mesenchymal transition of A549 lung cancer cells exposed to electronic cigarettes

Permalink

<https://escholarship.org/uc/item/5dj9r5g7>

Authors

Zahedi, Atena

Phandthong, Rattapol

Chaili, Angela

et al.

Publication Date

2018-08-01

DOI

10.1016/j.lungcan.2018.06.010

Peer reviewed

Epithelial-to-Mesenchymal Transition of Lung Cancer Cells Exposed to Electronic Cigarettes

Atena Zahedi ^{1,2}, Rattapol Phandthong ², Angela Chaili ², Guadalupe Lemark ², and Prue Talbot

^{1,2}

¹Department of Bioengineering

²Department of Molecular, Cell and Systems Biology

University of California,

Riverside, California, USA

Corresponding author: Prue Talbot, Department of Molecular, Cell and Systems Biology,
University of California, Riverside, CA. 92521

Telephone: 951-850-7783

Email address of corresponding author: talbot@ucr.edu

ABSTRACT

Objectives: Epithelial-to-mesenchymal transition (EMT) is the initial step enabling the metastasis of cancer cells, which typically leads to death. Although smoking is a major risk factor for lung cancer, there is still widespread use of conventional cigarettes. Recently, the tobacco industry has been transformed by the introduction of electronic cigarettes (ECs), which have lower levels of carcinogens and may provide a safer alternative. Here, we investigate the ability of EC liquids and aerosols to induce an EMT in lung cancer cells.

Materials and Methods: Human adenocarcinoma alveolar basal epithelial cells (A549) were exposed to EC liquids and aerosols from a popular product for 3-8 days. Live cell imaging, EMT biomarker analysis, and machine learning/image processing algorithms were used to characterize changes associated with EMT.

Results: Long-term exposure of A549 cells to menthol or tobacco-flavored EC liquids or aerosols induced an EMT accompanied by acquisition of a fibroblast-like morphology, loss of cell-to-cell junctions, internalization of E-cadherin, increased motility, and upregulation of EMT markers. The EMT was concurrent with plasma membrane to nuclear translocation of β -catenin.

Conclusion: This is the first known study to show an EMT of lung cancer cells during exposure to EC products. Because an EMT is an initial step leading to metastasis, an intractable problem that often leads to death, this critical finding has significant implications for former or heavy cigarette smokers who are using EC and may be at risk for lung cancer or who may already have a lung tumor.

Keywords: Electronic cigarette, Tobacco products, Metastasis, Lung cancer, Epithelial-to-mesenchymal transition, β -catenin

1. Introduction

Metastasis is a multi-step process in which cancer cells undergo an epithelial-to-mesenchymal transition (EMT), then detach from the primary tumor, and migrate to neighboring or distant organs, where they proliferate and create new tumors [1]. Once cancer cells have metastasized, treatment becomes very difficult, and the chances of survival are diminished. Lung cancer accounts for the highest number of cancer-related deaths, most of which are due to the metastasis of tumor cells [2,3].

Tobacco use is the main risk factor for lung cancer and is responsible for approximately 22% of cancer-related deaths globally [4]. Cigarette smoke promotes metastasis through induction of an EMT in existing airway epithelial tumors by down-regulating epithelial cadherin (E-cadherin), which leads to loss of cell–cell adhesion and apical–basal polarity [5–7].

Electronic cigarettes (EC) are tobacco products that have rapidly gained worldwide acceptance and are often promoted as harm-reduction or smoking-cessation alternatives [8]. Their introduction into world markets has come without much prior research on their potential to cause cancer or effect cancer progression. Prior in vitro studies on EC have focused on their toxicity [9,10], with one recent in vitro study showing that EC aerosol produced little mutagenicity [11]. These studies were all done over relatively short exposure periods, usually lasting only 24-48 hours. Other conflicting studies demonstrated that EC exposure results in carcinogenic transformation in *Salmonella typhimurium* [12] and a rat lung model [13], which may not be comparable to humans.

No study to date has examined the potential for EC to cause an EMT and contribute to the progression of a pre-existing cancer. In this study, we tested the hypothesis that longer exposures of lung cancer cells to EC liquids and aerosols, typical of those EC users receive, induces an EMT, thereby creating the potential for metastasis.

2. Materials and Methods

2.1 EC liquids and aerosols

Menthol and tobacco flavors of a leading product of cartomizer style EC were purchased at local markets in Southern California. Liquids were removed from cartomizers by centrifugation, and 1% dilutions by volume were prepared in A549 culture medium. Aerosols were generated using a smoking machine by taking 4.3 sec puffs (average for EC users) every 1 minute with an adjusted flow rate to produce a consistent robust puff. Aerosols were collected in A549 culture medium in a 250 mL round-bottom flask, which was suspended in an ethanol and dry ice bath to allow immediate condensation and capture of aerosol puffs. After collection, medium was warmed to room temperature, aliquoted, then immediately frozen and stored at -80°C until used. Six puffs were dissolved per 1 mL of A549 culture medium, which is referred to as 6 total-puff-equivalents (TPE) of aerosol. Both e-liquids and aerosols were passed through a 0.2µm filter before use in experiments.

2.2 Long-term culturing of A549 lung cancer cells

A549 CCL-185 cells (ATCC, Manassas, VA USA), which were previously derived from a human lung adenocarcinoma, were grown on non-coated T-25 flasks and cultured in ATCC F-12 K medium with 10% A549-specific fetal bovine serum in 5% CO₂ at 37°C. Cells were incubated in control medium or medium containing dilutions of aerosol or EC liquid until 80% confluent, then passaged using 0.25% trypsin, and grown in control or treatment medium for 3-8 days.

2.3 Morphological analysis

Cell morphology was classified as cobblestone (normal morphology), enlarged, or elongated using CL-Quant (DR Vision, Seattle WA) and CellProfiler image processing software [14] and a custom machine learning algorithm written in Matlab software (MathWorks Natick, MA, USA). Each image was segmented using CL-Quant software and manually modified to

separate individual cells. The binary image of the segmentation was exported into CellProfiler to extract 61 morphological features from which six (area, compactness, eccentricity, major axis length, minor axis length, and solidity) were used to develop a learning library. A library consisting of 126 cells was manually classified to provide ground truth for the three morphological classes. Next, 10-fold cross-validation was conducted resulting in 97% accuracy in classification. Three separate (untrained) datasets consisting of 359 cells were run through the supervised machine learning algorithm and were validated manually, resulting in 89% accuracy. Datasets presented in this paper were automatically analyzed using this classifier.

2.4 Immunocytochemistry

Immunocytochemistry was performed using antibodies to EMT markers that included E-cadherin and vimentin (Millipore, Burlington, MA, USA), metalloproteinase 9 (MMP9) and P120 (Abcam, Cambridge, MA, USA), and non-phospho (active) β -catenin (Cell Signaling, Danvers, MA, USA). Also, an early endosome antigen 1 (EEA1) antibody (Cell Signaling, Danvers, MA, USA) was used for the E-cadherin co-localization study. Briefly, cells were grown in Ibidi chamber slides (Ibidi, Munich, Germany) and fixed using 4% paraformaldehyde. Cells were blocked in 10% donkey serum (Sigma-Aldrich, St. Louis, MO, USA) in 0.1% Triton-X (Bio-Rad, Hercules, CA, USA) in PBS, and primary antibodies were diluted in 0.2% Tween (Sigma-Aldrich, St. Louis, MO, USA) in PBS and incubated at 4°C overnight. Cells were next washed in PBS then incubated in Alexa Fluor 594 and 488 secondary antibodies (Life Technologies, Eugene OR USA) at room temperature for 1 hour, then mounted in Vectashield (Vector Laboratories, Burlingame, CA USA).

2.5 E-cadherin transfection and internalization

For the E-cadherin/EEA1 co-localization study, cells were first transfected with an E-cadherin-GFP plasmid (Addgene #28009, Cambridge, MA USA). Briefly, cells were plated the

day before transfection, a DNA-In A549 transfection reagent was used (MTI-GlobalStem, Gaithersburg, MD USA), and cells were incubated for 18-24 hours to allow gene expression. Next, the transfected cells were trypsinized and re-plated with EC liquids or aerosol for 4 days. Lastly, cells were immuno-labeled with an early endosome marker, EEA1, to demonstrate co-localization and internalization of E-cadherin into endocytic vesicles.

To confirm co-localization of E-cadherin and EEA1, a line scanning method was used. Briefly, intensity data for representative images in Figures 4A-E were collected by the line intensity tool in Nikon Elements Advanced Research software (Nikon Instruments, Melville, NY). Lines with a relative length equivalent to 35 μm were drawn on representative images. Pixel intensity data were collected along the line from both green (E-cadherin) and red (EEA1) channels. To rescale intensity data to a 0 to 1 range, raw intensity data were normalized with the feature scaling equation:

$$z_i = \frac{x_i - \min(x)}{\max(x) - \min(x)}$$

where z_i represents the normalized intensity value, which was computed using min and max intensity values in the set x . x_i represents the intensity value before normalization. Normalized intensity values were plotted using GraphPad Prism.

2.6 Fluorescence and phase contrast microscopy

Time-lapse fluorescent images were collected using an inverted Eclipse Ti-E microscope (Nikon Instruments, Melville, NY) equipped with a 60X objective (numerical aperture 0.85) and captured on the high-resolution Andor Zyla VSC-04941 camera (Andor, Belfast, UK). The live cells were placed in a LiveCell incubation chamber (Pathology Devices Inc., San Diego CA USA), which were kept at 37°C, 5% CO₂, and 90% relative humidity. The images were de-convoluted using the Live De-blur setting in the Nikon NIS Elements software. Fluorescence

analysis was quantified using CellProfiler and CL-Quant software (DR Vision, Seattle, WA). Phase contrast time-lapse videos of A549 cells were captured in a BioStation CT Incubator (Nikon Instruments, Tokyo, Japan).

2.7 Motility and Migration Analysis

Phase contrast and Hoechst 33342 (ImmunoChemistry Technologies, Bloomington, MN USA) fluorescent time-lapse images were captured every 15 minutes using a BioStation CT. CL-Quant software was used to track and extracted motility information. First, the tophat preprocessing method was used to remove noise and strengthen the signal in the Hoechst (blue) channel (excitation 350nm). Small object removal and background subtraction procedures were applied to minimize background noise. The tracking procedure was applied to the final signal segmentation to create trajectory tracks for cells with fluorescent signal. Tracking data were exported to Excel and imported into Matlab to generate migratory graphs, which displayed the total length traveled and the initial-final position displacement for each cell. Three independent experiments were done for each parameter studied, and statistical analyses were done using one-way ANOVAs with Prism (GraphPad, San Diego, CA USA) and Minitab software (State College, PA USA).

2.8 Quantification of β -catenin

β -catenin and P120 were visualized using immunocytochemistry and nuclei were labeled with DAPI-Vectashield (Vector Laboratories, Burlingame, CA USA). For the β -catenin (red channel) signals, images were first smoothed to normalize uneven pixel distribution and rescaled to stretch the fluorescence signal from 0 to 1. Tophat and bottomhat methods were used to enhance the signal, and adaptive MOG thresholding was applied to remove noise. Otsu's method was used to extract fluorescent β -catenin signals. β -catenin and nuclei segmentations were co-localized. The percent of β -catenin counts or area inside the nucleus

was calculated by dividing the co-localized signal by the total β -catenin signal. For both area and count data, statistical analyses were done on arcsine transformed percent data using a one-way ANOVA with Dunnett's post hoc test, in which treated groups were compared to the control.

2.8 Quantification of P120 internalization

For P120, images were imported into CI-Quant for analysis. First, tophat was used to remove haze and background noise. P120 signals were segmented using the threshold method. The P120 signal was divided into two parts, internalized signal and tight junction signal. At the tight junction, P120 signals were band-like, whereas internalized P120 was punctate. Punctate signals were filtered out based on their size. The remaining signals were then skeletonized to enhance the band-like morphology. Non-band-like signals were then removed by size. The remaining skeletonized band-like signals were used as guides for the co-localization filtering method. Signals that co-localized with skeletonize bands were placed in a tight junction bin and signals that did not were placed in an internalized object bin. Counts and area information were extracted from both bins. The percent of internalized P120 counts or area was extracted by dividing internalized P120 by the total P120 signals. One-way ANOVAs with Dunnett's post hoc test were performed on the percent data, in which treated groups were compared to the control group.

3. Results

3.1 EC E-liquids and aerosols induce morphological changes consistent with an EMT

A549 cells normally grow as tightly adhering "cobblestone" monolayers with a few elongated and large cells interspersed among the cobblestone cells (Fig. 1A). The relative abundance of each cell type was evaluated using a custom protocol developed with CI-Quant,

CellProfiler, and Matlab software. By 3-4 days of treatment with e-liquid or aerosol, there was a significant decrease in the cobblestone cells and a corresponding increase in single elongated mesenchymal-like cells, consistent with an EMT (Figs. 1A-D). There was also an increase in the enlarged cells, which were more pronounced in the e-liquid treatments (Figs. 1B, 1D). In time-lapse videos, e-liquid and aerosol treated cells made repeated unsuccessful attempts to adhere with neighboring cells, whereas control cells formed tight cell-to-cell connections (Figs. 1E-G). In Figures 1E-G, each individual cell was numbered, and the progeny were followed over time.

3.2 Molecular Markers of an EMT

To confirm that the above changes were due to an EMT, molecular markers characteristic of cells transitioning from an epithelial-to-mesenchymal phenotype were used. Cancer cell-produced MMP9 is required for invasion through the extracellular matrix during metastasis [16]. MMP9 was upregulated by day 4 in A549 cells treated with either E-liquid or aerosol (Figs. 2A, 2C). By 8 days of treatment, E-cadherin was lost from the cell surface (Fig. 2B), consistent with the observed lack of cell-to-cell adhesion (Figs. 1E-G). Immunocytochemistry also revealed an increase in total vimentin (Figs. 2B, 2D integrated density) and an increase in vimentin cross points, indicative of increased density (Fig. 2E) after 8 days of treatment. Vimentin is overexpressed in epithelial cancers and facilitates accelerated tumor growth and invasion [17]. These changes in vimentin likely facilitate the transition of cells to a more elongated phenotype. These molecular marker data support the idea that EC treated cells undergo an EMT during 4-8-days of exposure.

3.3 Internalization of E-cadherin During the EMT

One of the primary modes of EMT initiation is the reduction of membrane E-cadherin via the endocytic machinery. To assess whether the decrease in E-cadherin expression at the cell membrane was due to its internalization, 4 day-treated A549 cells were transfected with an E-

cadherin plasmid and then immuno-labeled with an early endosome marker (EEA1). The control cells revealed very few co-localized signals; whereas both the menthol and tobacco E-liquid and aerosol treated groups had distinct co-labeled puncta indicative of internalized E-cadherin cargo (Figs. 3A-F). Accumulation of E-cadherin was seen in the perinuclear region (Fig. 3C, white arrow)

3.4 Treatment with EC liquid and aerosol increases cell motility

An increase in cell motility is characteristic of cancer cells undergoing an EMT [18]. To determine if EC-treatment enhanced cell migration, A549 cells were labeled with the Hoechst 33342 live cell nuclear dye and monitored over time in a BioStation CT. A dual fluorescence and phase contrast tracking algorithm was developed to monitor the motility of each cell. Cells treated with E-liquids and aerosols for 3-4 days showed an increase in the population of motile cells (total distance traveled > 30 μm) (Figs. 4A-E). Migration graphs also showed that control cells mainly exhibited a random-walk (Brownian) type motion, whereas most of the treated cells exhibited a “directed” movement (Figs. 4A-C).

3.5 Translocation of β -catenin and P120 from the plasma membrane to the cytoplasm and nucleus

Immunocytochemistry was performed to compare the localization of β -catenin and P120, two adherens junction proteins important in cell polarity, in the control and treated groups. In treated cells, the non-phosphorylated form of β -catenin showed a marked decrease in cell junctions and a corresponding increase inside the cells (Fig. 5A). If de-phosphorylated, β -catenin is stabilized and protected against degradation by GSK-3 β and can move into the nucleus to initiate transcription. Image processing software was used to quantify co-localization of β -catenin with the nuclear DAPI-stain. A significant increase in the number and area (%) of β -catenin puncta in the nucleus was observed in treated cells (Figs. 5B-C). Treatment of A549

cells with E-liquid or aerosol caused a decrease in P120 at the cell membranes (Fig. 5D) and an increase in cytoplasmic levels (percent of P120 internalized by area and count shown in Figs. 5E and 5F respectively). Unlike β -catenin, P120 did not show an accumulation in the nuclei of aerosol treated groups (Fig. 5D), and therefore was not quantified.

4. Discussion

This study is the first to examine multiday exposure of cancer cells to EC liquids and aerosols and to report that such exposure causes changes in cell morphology, cell-to-cell adhesion, molecular markers, and motility consistent with an EMT. These changes include transformation of cobblestone monolayers to mesenchymal-like cells, decreased E-cadherin, increased vimentin and MMP9, and increased cell motility. There was also an increase in the number of cells with an enlarged phenotype, consistent with a case report in which a lung biopsy from an EC user had multinucleated giant cells [19]. An EMT was induced in A549 cells by both the menthol and tobacco flavored EC liquids and aerosols from the leading product of EC used in this study. This shows that the factor(s) causing the EMT is present in the fluid before heating and is not a chemical produced as a result of aerosolization. EC users do sometimes draw E-liquid into their mouths and get E-liquid on their skin. Although not a topic in this study, there is a possibility that a similar EMT would occur in tumors localized in these tissues as well.

The EC-induced EMT was accompanied by the internalization of E-cadherin via endocytosis into early endosomes with subsequent accumulation in the perinuclear region, which may be the endocytic recycling compartment (ERC) [20]. Loss of E-cadherin from junctional complexes is a ubiquitous feature of an EMT and a necessary step that enables subsequent cell migration away from a tumor during metastasis [18]. We also observed enhanced migration of cells that were no longer able to adhere to other cells.

EC treatment also resulted in the translocation of β -catenin and P120 catenin from the plasma membrane to the cytoplasm, and β -catenin was further translocated to the nucleus. β -catenin and P120 are essential components of the cadherin-based adherens junctions, and their cytoplasmic accumulation likely contributes to the destabilization of cell junctions. Other studies have shown that the transport of these catenins to the nucleus activates the Wnt-signaling (β -catenin) and Rho GTPase (P120) pathways, which in turn contribute to an EMT [20,21]. The appearance of β -catenin in the nucleus following EC liquid or aerosol treatment suggests that the EMT observed in our study was further activated by the Wnt/ β -catenin pathway.

An EMT is a critical initiation step in the metastasis of lung cancer cells. During an EMT, epithelial cells lose their polarity, cell-cell junctions, and cell-matrix adhesions, allowing them to migrate and invade other tissues, often remote from the primary tumor. A549 adenocarcinoma cells are part of the non-small cell lung cancer (NSCLC) group. Once such cells have undergone an EMT and metastasized in patients, treatment is difficult and survival rates are very low (five-year survival rate for stage 4 NSCLC is less than 1%) (American Cancer Society web reference).

ECs are often promoted as harm reduction products, and Public Health England has stated that they are 95% safer than conventional cigarettes [22]. These claims are often based on the observation that EC aerosols have fewer chemicals than conventional cigarettes and harmful chemicals are usually lower in concentration in ECs [23]. However, most work done on cell and animal responses to EC aerosol have not to-date looked for metastasis. One recent paper describes the formation of tumors in rat lungs exposed to EC aerosol [13]. Our data are the first to show an EMT in human lung cancer cells, a critical observation that suggests EC might lead to metastasis of existing tumors. While additional work will be required to determine if a similar EMT occurs in humans using EC, our data demonstrate an important need for additional information on this topic.

Conventional cigarette constituents induce tumor formation and to contribute to cancer progression by initiating an EMT [6,7,16,24–26]. The effects induced by EC liquids and aerosols are similar to those reported for cigarette smoke, which include morphological changes, increased migratory behavior, and initiation of EMT signaling pathways. This again calls into question the safety of ECs and raises concerns about their designation as harm reduction products.

The aerosol concentration used in our study corresponds to what a user would receive while inhaling 6 puffs of EC aerosol. Although puffing topography varies with each individual [27], an average user puffs roughly 175 times/day [28]. While our work was done using continuous exposure over multiple days, the concentration of aerosol during our exposures was less than the total exposure an EC user would receive in a day (6 TPE vs 175 puffs/day). It will be important in future work to mimic human inhalation of EC aerosol with in vitro models that use intermittent air liquid interface exposure.

It is not yet known if all products of EC products cause a similar EMT during multiday exposures. Since the EMT was observed with a leading EC product, the number of users who could potentially be impacted is high. This critical finding has significant implications for former cigarette users who have switched to EC and may be at risk for lung cancer or who may already have a lung tumor. Given these findings, it would be advisable for health care workers to include EC use in patient medical records, particularly those with a history of cigarette smoking or dual use of EC and tobacco cigarettes. These data bring to focus the overall need for better understanding of the effects of ECs on health, particularly with respect to cancer progression. This study further supports the 2016 Surgeon General's conclusion that EC aerosol is not harm-free [8] and that the FDA may need to regulate ECs under its authority.

Author Affiliations: Bioengineering Graduate Program, University of California, Riverside, California (Zahedi); Department of Molecular, Cell and Systems Biology, University of California, Riverside, California (Zahedi, Phandthong, Chaili, Lemark, Talbot).

Corresponding Author: Dr. Prue Talbot (PhD), Department of Molecular, Cell and Systems Biology, University of California, Riverside, CA 92521 (talbot@ucr.edu).

Author Contributions: Dr. Talbot had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Concept and design: Zahedi and Talbot

Acquisition of data: Zahedi

Analysis and interpretation of data: All authors.

Drafting of the manuscript: Zahedi and Talbot

Critical revision of the manuscript for important intellectual content: All authors.

Obtained funding: Talbot

Administrative, technical, or material support: Talbot

Supervision: Talbot

Conflict of Interest Disclosures: All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest and none were reported.

Funding/Support: Research reported in this publication was supported by the National Institute on Drug Abuse of the National Institutes of Health under Award Numbers R01DA036493 and R21DA037365.

Role of the Funder/Sponsor: The study funder had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; or decision to submit the manuscript for publication.

Disclaimer: This content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

References

- [1] J.E. Talmadge, I.J. Fidler, AACR centennial series: The biology of cancer metastasis: Historical perspective, *Cancer Res.* 70 (2010) 5649–5669. doi:10.1158/0008-5472.CAN-10-1040.
- [2] B.W. Stewart, C.P. Wild, World cancer report 2014, *World Heal. Organ.* (2014) 1–2. doi:9283204298.
- [3] D. Spano, C. Heck, P. De Antonellis, G. Christofori, M. Zollo, Molecular networks that regulate cancer metastasis, *Semin. Cancer Biol.* 22 (2012) 234–249. doi:10.1016/j.semcancer.2012.03.006.
- [4] M.H. Forouzanfar, A. Afshin, L.T. Alexander, S. Biryukov, M. Brauer, K. Cercy, Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015, *Lancet.* 388 (2016) 1659–1724. doi:10.1016/S0140-6736(16)31679-8.

- [5] CDC, What Are the Risk Factors for Lung Cancer?, www.cdc.gov. (2017).
- [6] E. Veljkovic, J. Jiricny, M. Menigatti, H. Rehrauer, W. Han, Chronic exposure to cigarette smoke condensate in vitro induces epithelial to mesenchymal transition-like changes in human bronchial epithelial cells, BEAS-2B, *Toxicol. Vitro.* 25 (2011) 446–453.
doi:10.1016/j.tiv.2010.11.011.
- [7] L. Zhang, M. Gallup, L. Zlock, C. Basbaum, W.E. Finkbeiner, N.A. McNamara, Cigarette smoke disrupts the integrity of airway adherens junctions through the aberrant interaction of p120-catenin with the cytoplasmic tail of MUC1, *J. Pathol.* 229 (2013) 74–86.
doi:10.1002/path.4070.
- [8] V.H. Murthy, E-Cigarette Use Among Youth and Young Adults: A Report of the Surgeon General, 2016.
- [9] R.Z. Behar, B. Davis, Y. Wang, V. Bahl, S. Lin, P. Talbot, Identification of toxicants in cinnamon-flavored electronic cigarette refill fluids, *Toxicol. Vitro.* 28 (2014) 198–208.
doi:10.1016/j.tiv.2013.10.006.
- [10] V. Bahl, S. Lin, N. Xu, B. Davis, Y.H. Wang, P. Talbot, Comparison of electronic cigarette refill fluid cytotoxicity using embryonic and adult models, *Reprod. Toxicol.* 34 (2012) 529–537. doi:10.1016/j.reprotox.2012.08.001.
- [11] S. Tommasi, S.E. Bates, R.Z. Behar, P. Talbot, A. Besaratinia, Limited mutagenicity of electronic cigarettes in mouse or human cells in vitro, *Lung Cancer.* 112 (2017) 41–46.
doi:10.1016/j.lungcan.2017.07.035.
- [12] D. Thorne, I. Crooks, M. Hollings, A. Seymour, C. Meredith, M. Gaca, The mutagenic assessment of an electronic-cigarette and reference cigarette smoke using the Ames assay in strains TA98 and TA100, *Mutat. Res. - Genet. Toxicol. Environ. Mutagen.* 812 (2016) 29–38. doi:10.1016/j.mrgentox.2016.10.005.
- [13] D. Canistro, F. Vivarelli, S. Cirillo, C.B. Marquillas, A. Buschini, M. Lazzaretti, L. Marchi, V. Cardenia, M.T. Rodriguez-Estrada, M. Lodovici, C. Cipriani, A. Lorenzini, E. Croco, S.

- Marchionni, P. Franchi, M. Lucarini, V. Longo, C.M. Della Croce, A. Vornoli, A. Colacci, M. Vaccari, A. Sapone, M. Paolini, E-cigarettes induce toxicological effects that can raise the cancer risk, *Sci. Rep.* 7 (2017) 1–9. doi:10.1038/s41598-017-02317-8.
- [15] A.E. Carpenter, T.R. Jones, M.R. Lamprecht, C. Clarke, I.H. Kang, O. Friman, D. a Guertin, J.H. Chang, R. a Lindquist, J. Moffat, P. Golland, D.M. Sabatini, CellProfiler: image analysis software for identifying and quantifying cell phenotypes., *Genome Biol.* 7 (2006) R100. doi:10.1186/gb-2006-7-10-r100.
- [16] S. Heerboth, G. Housman, M. Leary, M. Longacre, S. Byler, K. Lapinska, A. Willbanks, S. Sarkar, EMT and tumor metastasis, *Clin. Transl. Med.* 4 (2015) 6. doi:10.1186/s40169-015-0048-3.
- [17] H.H. Popper, Progression and metastasis of lung cancer, *Cancer Metastasis Rev.* 35 (2016) 75–91. doi:10.1007/s10555-016-9618-0.
- [18] A.W. Lambert, D.R. Pattabiraman, R.A. Weinberg, Emerging Biological Principles of Metastasis, *Cell.* 168 (2017) 670–691. doi:10.1016/j.cell.2016.11.037.
- [19] L.R. Madsen, N.H.V. Krarup, T.K. Bergmann, S. Brentzen, S. Neghabat, L. Duval, S.T. Knudsen, A cancer that went up in smoke pulmonary reaction to e-cigarettes imitating metastatic cancer, *Chest.* 149 (2016) e65–e67. doi:10.1016/j.chest.2015.09.003.
- [20] Y. Kam, V. Quaranta, Cadherin-bound β -catenin feeds into the Wnt pathway upon adherens junctions dissociation: Evidence for an intersection between β -catenin pools, *PLoS One.* 4 (2009). doi:10.1371/journal.pone.0004580.
- [21] A.B. Reynolds, Epithelial organization: New perspective on α -catenin from an ancient source, *Curr. Biol.* 21 (2011) R430–R432. doi:10.1016/j.cub.2011.04.043.
- [22] A. McNeill, L.S. Brose, R. Calder, S.C. Hitchman, P. Hajek, M. H, E-cigarettes : an evidence update A report commissioned by Public Health England, 2015.
www.gov.uk/government/uploads/system/uploads/attachment_data/file/454516/Ecigarette_s_an_evidence_update_A_report_commissioned_by_Public_Health_England.pdf.

- [23] M.L. Goniewicz, J. Knysak, M. Gawron, L. Kosmider, A. Sobczak, J. Kurek, A. Prokopowicz, M. Jablonska-Czapla, C. Rosik-Dulewska, C. Havel, P. Jacob, N. Benowitz, Levels of selected carcinogens and toxicants in vapour from electronic cigarettes, *Tob. Control.* 23 (2014) 133–139. doi:10.1136/tobaccocontrol-2012-050859.
- [24] W. Zou, Y. Zou, Z. Zhao, B. Li, P. Ran, Nicotine-induced epithelial-mesenchymal transition via Wnt/ β -catenin signaling in human airway epithelial cells, *Am. J. Physiol. Cell. Mol. Physiol.* 304 (2013) L199–L209. doi:10.1152/ajplung.00094.2012.
- [25] P. Dasgupta, W. Rizwani, S. Pillai, R. Kinkade, M. Kovacs, S. Banerjee, M. Carless, E. Kim, D. Coppola, Nicotine induces cell proliferation, invasion and epithelial- mesenchymal transition in a variety of human cancer cell lines, *Int. J. Cancer.* 124 (2009) 36–45. doi:10.1002/ijc.23894.
- [26] S.A. Grando, Connections of nicotine to cancer, *Nat. Rev. Cancer.* 14 (2014) 419–429. doi:10.1038/nrc3725.
- [27] R.Z. Behar, M. Hua, P. Talbot, Puffing topography and nicotine intake of electronic cigarette users, *PLoS One.* 10 (2015) 1–18. doi:10.1371/journal.pone.0117222.
- [28] J.F. Etter, Electronic cigarettes: A survey of users, *BMC Public Health.* 10 (2010). doi:10.1186/1471-2458-10-231.

Web Reference

American Cancer Society <https://www.cancer.org/cancer/non-small-cell-lung-cancer/detection-diagnosis-staging/survival-rates.html> . Accessed 4-3-2018.

Figure Legends

Figure 1: A549 Cell Morphology after EC Treatment. (A-C) Control A549 cells and cells treated 3-4 days with e-liquid and aerosol were image processed to quantify the percent of cobblestone (white), enlarged (yellow), and elongated (red) morphologies. (D) E-liquid and

aerosol treatment decreased the cobblestone and increased the elongated (mesenchymal-like) sub-populations. Each error bar is the mean \pm standard error of the mean (SEM) of three independent experiments. Statistical analysis was done on arcsine transformed data using a one-way ANOVA with Dunnett's post hoc test. (E-G) Film-strips show that control cells adhered with neighbors, while treated cells failed to adhere. Individual cells are labeled numerically and then labeled with an additional "a" and "b" to denote daughter cells produced by division. Red arrows point to loss of tight junction.

Figure 2: Upregulation of EMT Markers in E-liquid and Aerosol Treated Cells. (A) Immunofluorescence of 4-day treated A549 cells labeled with MMP9 antibody. (B) Immunofluorescence of 8-day treated A549 cells co-labeled with E-cadherin and vimentin antibodies. (C) Quantification of integrated density (total area \times mean intensity) of MMP9 fluorescent images. Each error bar is the mean \pm SEM of three independent experiments. (D-E) Integrated density and cross points of vimentin fluorescent images. Increase of integrated density and cross points are indicative of increased protein expression. Each error bar is the mean \pm SEM of five independent experiments. One-way ANOVAs with Dunnett's post hoc test were performed on natural log transformed data. Asterisks on top of each bar indicate the statistical significance. (* = $p < 0.05$. ** = $p < 0.01$. *** = $p < 0.001$. **** = $p < 0.0001$)

Figure 3: E-cadherin Internalization by Endocytosis. (A-E) 4-day treated A549 cells were transfected with an E-cadherin plasmid and co-immuno-labelled with an EEA1 antibody to demonstrate internalization of E-cadherin. A line scanning method was used to do intensity profiling to confirm the co-localization of the E-cadherin and EEA1 signals. Black arrowheads above each graph (except control) show co-localization of the two channels. (F) Enlarged image of 4-day menthol aerosol treated cells. Red arrows show co-localization of E-cadherin and EEA1.

Figure 4: Increased Motility after EC Treatment (A-C) Motility graphs show compilation of trajectories and distance traveled by individual control cells and treated cells (central circles are positioned 25 μ m from the starting location). Different colors correlate with different cells tracks. (D-E) The percent of “motile cells” (displacement > 25 μ m) increased in treated groups. Each error bar is the mean \pm SEM of four independent experiments. Motility data statistical analysis were done using a one-way ANOVA with Dunnett’s post hoc test; treated groups were compared to the control. Asterisks on top of each bar indicate the statistical significance. (* = $p < 0.05$. ** = $p < 0.01$.)

Figure 5: Translocation of Two Catenin-Family Transcription Factors. (A) Segmentation of active β -catenin (red and green) and nucleus (cyan). β -catenin puncta outside of the nucleus are outlined in red, and β -catenin puncta co-localized in the nucleus are outlined in green. (B-C) Quantification of percent area and counts of β -catenin puncta inside the nucleus. Nuclear co-localization percent was calculated by dividing nucleus co-localize β -catenin with total β -catenin. Each error bar is the mean \pm SEM of six independent experiments. One-way ANOVA with Dunnett’s post hoc test was performed on B and C arcsine-transformed percent data; treated groups were compared to control. (D) 8-day treated A549 cells immunolabeled with P120. (E-F) Quantification of the percent area and count of internalized P120. Each error bar is the mean \pm SEM of three independent experiments. One-way ANOVA with Dunnett’s post hoc tests were performed on E and F percent data. Internalized P120 signal percent were calculated by dividing internalized group with the total P120 signal. Asterisks on top of each bar indicate the statistical significant. (* = $p < 0.05$. ** = $p < 0.01$. *** = $p < 0.001$.)